Skip Navigation

Phone Service Update

We apologize that callers may intermittently experience longer than usual wait times. We are working with our phone service provider as they try to improve the situation as soon as possible.

COVID-19 Vaccine Information |Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts

Find a Doctor

Find a Researcher


Christopher Simon Hourigan, D.M., D.Phil.

Photo of Dr. Christopher Simon Hourigan, D.M., D.Phil.

Specializes in: Adults (18+ years), Geriatrics (55+ years)



Acute Myeloid Leukemia (AML), Allogeneic Bone Marrow Transplantation, Cancer Genetics, Hematologic Malignancies, Hematology Oncology, Hematology/Oncology, Immunotherapy, Inherited Hematologic Malignancies, Leukemia, Medical Oncology, Myelodysplastic Syndromes (MDS) more


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map

Sibley Memorial Hospital

Appointment Phone: 202-660-6500
5255 Loughboro Road NW
Johns Hopkins Kimmel Cancer Center
Washington, DC 20016 map
Phone: 202-660-6500 | Fax: 202-660-6501


Christopher S. Hourigan DM DPhil FACP FRCP is an oncologist and part-time associate professor of oncology at Johns Hopkins University School of Medicine.  He is a member of the leukemia program at the Sidney Kimmel Comprehensive Cancer Center.  Dr. Hourigan is board certified in internal medicine, hematology and medical oncology by the American Board of Internal Medicine.  

Dr. Hourigan received his medical degree and PhD from Oxford University, and completed postgraduate clinical training in London and Baltimore. He has particular interest in approaches to predict development or recurrence of myeloid malignancy. more

Departments / Divisions

  • Medicine at Sibley Memorial Hospital

Centers & Institutes



  • BM BCh, University of Oxford Medical School (2006)
  • DM, University of Oxford (2018)


  • Guy's Hospital (2007)
  • Johns Hopkins Bayview Medical Center / Internal Medicine (2009)


  • Johns Hopkins University School of Medicine / Medical Oncology (2012)
  • National Institutes of Health / Hematology (2012)

Board Certifications

  • American Board of Internal Medicine / Hematology (2013)
  • American Board of Internal Medicine / Internal Medicine (2010)
  • American Board of Internal Medicine / Medical Oncology (2013)

Research & Publications

Selected Publications

View all on Pubmed

Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12.PMID: 29330221

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17.PMID: 30333627

Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017 Jul;31(7):1482-1490. doi: 10.1038/leu.2017.113. Epub 2017 Apr 7.PMID: 28386105

Percival ME, Lai C, Estey E, Hourigan CS. Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. Blood Rev. 2017 Jul;31(4):185-192. doi: 10.1016/j.blre.2017.01.003. Epub 2017 Feb 2.PMID: 28190619

Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol. 2013 Aug;10(8):460-71. doi: 10.1038/nrclinonc.2013.100. Epub 2013 Jun 25.PMID: 23799371

Activities & Honors


  • Alpha Omega Alpha
  • Sidney Truelove Prize, Oxford University
  • Patrick Murphy Award for Resident Teaching, Johns Hopkins Bayview
  • Early Career Physician Award, American College of Physicians (VA)
  • Fellow, American College of Physicians
  • Honorary Fellow, Royal College of Physicians (London)
  • Presidential Early Career Award for Scientists and Engineers

Professional Activities

  • International Consensus Guidelines Committee on Measurable Residual Disease in Acute Myeloid Leukemia, European Leukemia Network (ELN), 2016
  • Co-Chair, Laboratory Assays Working Group, National Cancer Institute (NCI) Myeloid Malignancies Precision Medicine Initiative, MyeloMATCH, 2019
  • Co-Chair, Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), 2020
  • Editorial Board Member, Journal of Translational Medicine, 2013
  • Editorial Board Member, Clinical Hematology International, 2019
  • Editorial Board Member, VJHemOnc, 2019
  • Editorial Board Member, Bone Marrow Transplantation, 2020

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 


Is this you? Edit Profile
back to top button